Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dani Brunner

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Plos Currents|April 12, 2011
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington's DiseaseStephen Oakeshott, Fuat Balci, Igor Filippov, et al.
Nature Biotechnology|September 10, 2014
Scientific rigor and the art of motorcycle maintenanceMarcus Munafò, Simon Noble, William J Browne, et al.
Journal of Huntington'S Disease|July 27, 2014
Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's diseaseAndrew M Farrar, Carol A Murphy, Neil E Paterson, et al.
Plos Currents|September 18, 2013
Increased Body Weight of the BAC HD Transgenic Mouse Model of Huntington's Disease Accounts for Some but Not All of the Observed HD-like Motor DeficitsAndrea E Kudwa, Liliana B Menalled, Stephen Oakeshott, et al.
Plos Currents|July 19, 2013
High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington's DiseaseFuat Balci, Stephen Oakeshott, Jul Lea Shamy, et al.
Plos One|August 8, 2013
SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognitionJesse E Hanson, Hank La, Emile Plise, et al.
Journal of Medicinal Chemistry|September 13, 2011
Discovery of isoxazole analogues of sazetidine-A as selective α4β2-nicotinic acetylcholine receptor partial agonists for the treatment of depressionJianhua Liu, Li-Fang Yu, J Brek Eaton, et al.
Pharmacology Research & Perspectives|December 16, 2014
The potent and selective α4β2*/α6*-nicotinic acetylcholine receptor partial agonist 2-[5-[5-((S)Azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol demonstrates antidepressive-like behavior in animal models and a favorable ADME-tox profileLi-Fang Yu, J Brek Eaton, Han-Kun Zhang, et al.
Plos One|January 4, 2013
Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175Liliana B Menalled, Andrea E Kudwa, Sam Miller, et al.
Nature Biotechnology|July 5, 2016
Large-scale phenome analysis defines a behavioral signature for Huntington's disease genotype in miceVadim Alexandrov, Dani Brunner, Liliana B Menalled, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Plos Currents|April 12, 2011
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington's DiseaseStephen Oakeshott, Fuat Balci, Igor Filippov, et al.
Nature Biotechnology|September 10, 2014
Scientific rigor and the art of motorcycle maintenanceMarcus Munafò, Simon Noble, William J Browne, et al.
Journal of Huntington'S Disease|July 27, 2014
Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's diseaseAndrew M Farrar, Carol A Murphy, Neil E Paterson, et al.
Plos Currents|September 18, 2013
Increased Body Weight of the BAC HD Transgenic Mouse Model of Huntington's Disease Accounts for Some but Not All of the Observed HD-like Motor DeficitsAndrea E Kudwa, Liliana B Menalled, Stephen Oakeshott, et al.
Plos Currents|July 19, 2013
High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington's DiseaseFuat Balci, Stephen Oakeshott, Jul Lea Shamy, et al.
Plos One|August 8, 2013
SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognitionJesse E Hanson, Hank La, Emile Plise, et al.
Journal of Medicinal Chemistry|September 13, 2011
Discovery of isoxazole analogues of sazetidine-A as selective α4β2-nicotinic acetylcholine receptor partial agonists for the treatment of depressionJianhua Liu, Li-Fang Yu, J Brek Eaton, et al.
Pharmacology Research & Perspectives|December 16, 2014
The potent and selective α4β2*/α6*-nicotinic acetylcholine receptor partial agonist 2-[5-[5-((S)Azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol demonstrates antidepressive-like behavior in animal models and a favorable ADME-tox profileLi-Fang Yu, J Brek Eaton, Han-Kun Zhang, et al.
Plos One|January 4, 2013
Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175Liliana B Menalled, Andrea E Kudwa, Sam Miller, et al.
Nature Biotechnology|July 5, 2016
Large-scale phenome analysis defines a behavioral signature for Huntington's disease genotype in miceVadim Alexandrov, Dani Brunner, Liliana B Menalled, et al.
Pageof 4